Study data showed more than half of patients who used targeted systemic therapies modified treatment due to lack of efficacy

Among patients surveyed in the study, 94% of those open to a new systemic therapy expressed interest in molecular testing to help identify a more effective treatment

FRIENDSWOOD, Texas, Sept. 24, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of a new study highlighting the challenges patients with atopic dermatitis (AD) experience in achieving their treatment goals and strong patient interest in molecular testing to help guide systemic therapy selection. The findings support the clinical need for molecular guidance in AD care. Castle's AdvanceAD-Tx test is designed to address this need by helping personalize systemic therapy decisions based on an individual patient's underlying disease biology.